November 23, 2016 - By Marguerite Chambers
New York: In a research note revealed to investors and clients on Wednesday, 23 November, Stifel maintained their Hold rating on shares of Medtronic (NYSE:MDT). They currently have a $81 PT on the company. Stifel’s target indicates a potential upside of 9.76% from the company’s current stock price.
Out of 17 analysts covering Medtronic (NYSE:MDT), 13 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 76% are positive. $102 is the highest target while $82 is the lowest. The $90.43 average target is 22.53% above today’s ($73.8) stock price. Medtronic has been the topic of 23 analyst reports since August 10, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the stock with “Outperform” rating in Tuesday, September 29 report. The stock of Medtronic PLC (NYSE:MDT) has “Buy” rating given on Friday, August 26 by Needham. As per Thursday, October 8, the company rating was upgraded by Evercore. Credit Suisse maintained Medtronic PLC (NYSE:MDT) rating on Monday, November 23. Credit Suisse has “Outperform” rating and $85 price target. The stock has “Buy” rating given by SunTrust on Monday, April 25. The stock of Medtronic PLC (NYSE:MDT) has “Buy” rating given on Thursday, June 2 by Deutsche Bank. The stock of Medtronic PLC (NYSE:MDT) has “Buy” rating given on Tuesday, August 23 by Citigroup. The rating was initiated by UBS with “Buy” on Tuesday, September 22. The firm earned “Conviction Buy List” rating on Friday, November 13 by Goldman Sachs. The company was maintained on Wednesday, June 1 by Wedbush.
About 360,948 shares traded hands. Medtronic PLC (NYSE:MDT) has declined 6.27% since April 21, 2016 and is downtrending. It has underperformed by 11.60% the S&P500.
Insitutional Activity: The institutional sentiment decreased to 0.73 in Q2 2016. Its down 0.07, from 0.8 in 2016Q1. The ratio fall, as 60 funds sold all Medtronic PLC shares owned while 508 reduced positions. 93 funds bought stakes while 361 increased positions. They now own 1.03 billion shares or 1.89% more from 1.01 billion shares in 2016Q1.
Moreover, Vanguard Inc has 0.52% invested in Medtronic PLC (NYSE:MDT) for 95.68 million shares. Tiger Eye Cap Lc last reported 170,213 shares in the company. Ubs Asset Mngmt Americas has 3.41 million shares for 0.33% of their US portfolio. Camarda Financial Advsrs Limited Co has 80 shares for 0% of their US portfolio. Amica Mutual Ins, a Rhode Island-based fund reported 74,595 shares. Roberts Glore And Inc Il holds 0.61% or 9,343 shares in its portfolio. Credit Agricole S A reported 1.20M shares or 0.4% of all its holdings. Mayo Advisers Ltd Limited Liability Company holds 3.35% or 193,350 shares in its portfolio. Holland Capital Management Limited Liability Company holds 2.19% or 650,890 shares in its portfolio. Wms Prns Limited Liability Corp has 8,033 shares for 0.1% of their US portfolio. Employees Retirement Of Texas holds 0.74% or 618,978 shares in its portfolio. Regions Corp last reported 0.38% of its portfolio in the stock. Modera Wealth Lc last reported 0.14% of its portfolio in the stock. Joel Isaacson Com Ltd Llc holds 0.01% or 621 shares in its portfolio. Cetera Advsr Limited Liability Corp holds 0.2% of its portfolio in Medtronic PLC (NYSE:MDT) for 29,270 shares.
Medtronic Public Limited Company is a medical technology and services company. The company has a market cap of $101.99 billion. The Firm develops, makes and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. It has a 28.68 P/E ratio. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
According to Zacks Investment Research, “Medtronic is the world’s leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The company’s product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.”
Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Firm operates in four divisions: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. The Company’s Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. The Company’s Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. The Company’s Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company’s subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
More important recent Medtronic PLC (NYSE:MDT) news were published by: Reuters.com which released: “Medtronic sales disappoint, firm lowers forecast; shares fall” on November 22, 2016, also Investorplace.com published article titled: “Why Medtronic PLC (MDT), Dycom Industries, Inc. (DY) and Palo Alto Networks …”, Investorplace.com published: “Medtronic PLC (MDT) Stock Oozes Long-Term Strength” on November 02, 2016. More interesting news about Medtronic PLC (NYSE:MDT) was released by: Seekingalpha.com and their article: “Medtronic Experiences The Downside Of Size” with publication date: November 23, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.